The most common CTC capture antibody is anti-epithelial cell adhesion molecules (EpCAM) CytoSorter® CTC system has been validated in BC (Jin et al., 2020), head and neck cancer (Zheng et al., 2019), pancreatic cancer (Wei et al., 2019) and lung cancer (Xie et al., 2021). This evidence concerns the gene EPCAM and head and neck cancer.